William Blair Assigns Outperform Rating to Enovis (ENOV)

Enovis Corporation (NYSE:ENOV) is one of the 10 Best Medical Stocks to Buy Under $30. On April 17, William Blair initiated coverage on Enovis Corporation (NYSE:ENOV), giving the stock an Outperform rating. The research firm pointed to valuation opportunities after the stock has dropped over the past two years.

William Blair said that Enovis Corporation (NYSE:ENOV) is trading at a price-to-earnings ratio of 9 times trailing earnings per share, including stock-based compensation. This is lower than the average of around 15.5 times for peers.

8William Blair Assigns Outperform Rating to Enovis (ENOV)

The research firm said that improving free cash flow will be the most important variable for Enovis Corporation’s (NYSE:ENOV) valuation to rise. Management guided free cash flow conversion to reach about 25% in 2026, compared to 10% in 2025. William Blair believes this target is achievable because of reduced cash charges from last year.

Additionally, William Blair supported management’s more conservative growth outlook for 2026, which is projected at 4% to 6%. This is lower than the guidance of more than 6% that the company gave heading into 2024 and 2025. The research firm believes that Enovis Corporation’s (NYSE:ENOV) valuation shows that investors are still skeptical about the company’s performance.

Enovis Corporation (NYSE:ENOV) is a medical technology company focused on developing clinically differentiated solutions in orthopedics and beyond.

While we acknowledge the risk and potential of ENOV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ENOV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Fintech Stocks to Invest In According to Billionaires and 10 Unrivaled Stocks of the Next 5 Years.

Disclosure: None.  Follow Insider Monkey on Google News.